Influence of phosphorus dendrimers on the aggregation of the prion peptide PrP 185-208

Barbara Klajnert, Marta Cortijo-Arellano, Josep Cladera, Jean Pierre Majoral, Anne Marie Caminade, Maria Bryszewska

Research output: Contribution to journalArticleResearchpeer-review

65 Citations (Scopus)


Inhibition of fibril assembly is a potential therapeutic strategy in prion diseases. The effect of cationic phosphorous dendrimers on the aggregation process of the prion peptide PrP 185-208 was studied using a spectrofluorometric assay with thioflavin T (ThT) and Fourier transformed infrared spectroscopy in order to monitor the kinetics of the process and the changes in the peptide secondary structure. The results show that phosphorous dendrimers are able to clearly interfere with PrP 185-208 aggregation process by both slowing down the formation of aggregates (by causing a decrease of the nucleation rate) and by lowering the final amount of amyloid fibrils, a common hallmark of conformational diseases. The dendrimers effect on the aggregation process would imply their interaction with peptide monomers and oligomers during the nucleation phase. © 2007 Elsevier Inc. All rights reserved.
Original languageEnglish
Pages (from-to)20-25
JournalBiochemical and Biophysical Research Communications
Issue number1
Publication statusPublished - 7 Dec 2007


  • Aggregation
  • Amyloid
  • Dendrimer
  • Fibril
  • Polymer
  • Prion disease


Dive into the research topics of 'Influence of phosphorus dendrimers on the aggregation of the prion peptide PrP 185-208'. Together they form a unique fingerprint.

Cite this